Global trends in research on miRNA–microbiome interaction from 2011 to 2021: A bibliometric analysis

Xiang-Yun Yan¹, Jun-Peng Yao¹, Yan-Qiu Li¹, Wei Zhang², Meng-Han Xi¹, Min Chen³ and Ying Li¹*

¹The Third Hospital/Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, China, ²Academic Affairs Office, Chengdu University of Traditional Chinese Medicine, Chengdu, China, ³Clinical Medicine School, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China

An increasing number of research suggests that the microRNA (miRNA)–microbiome interaction plays an essential role in host health and diseases. This bibliometric analysis aimed to identify the status of global scientific output, research hotspots, and frontiers regarding the study of miRNA–microbiome interaction over the past decade. We retrieved miRNA–microbiome-related studies published from 2011 to 2021 from the Web of Science Core Collection database; the R package bibliometrix was used to analyze bibliometric indicators, and VOSviewer was used to visualize the field status, hotspots, and research trends of miRNA–microbiome interplay. In total, 590 articles and reviews were collected. A visual analysis of the results showed that significant increase in the number of publications over time. China produced the most papers, and the United States contributed the highest number of citations. Shanghai Jiaotong University and the University of California Davis were the most active institutions in the field. Most publications were published in the areas of biochemistry and molecular biology. Yu Aiming was the most prolific writer, as indicated by the h-index and m-index, and Liu Shirong was the most commonly co-cited author. A paper published in the International Journal of Molecular Sciences in 2017 had the highest number of citations. The keywords “expression” and “gut microbiota” appeared most frequently, and the top three groups of diseases that appeared among keywords were cancer (colorectal, et al.), inflammatory bowel disease (Crohn’s disease and ulcerative colitis), and neurological disorders (anxiety, Parkinson’s disease, et al.). This bibliometric study revealed that most studies have focused on miRNAs (e.g., miR-21, miR-155, and miR-146a), gut microbes (e.g., Escherichia coli, Bifidobacterium, and Fusobacterium nucleatum), and gut bacteria metabolites (e.g., butyric acid), which have the potential to improve the diagnosis, treatment, and prognosis of diseases. We found that therapeutic strategies targeting the miRNA–microbiome axis focus on miRNA drugs produced in vitro; however, some studies suggest that in vivo fermentation can greatly increase the stability and reduce the degradation of miRNA. Therefore, this method is worthy of further research.
1 Introduction

Approximately 100 trillion microbes inhabit the human body (Peter et al., 2007), and nearly 95% of these microbes colonize the gastrointestinal tract. These microbes comprise a wide variety of species, including bacteria, viruses, parasites, and fungi (Kathryn and James, 2012). The microbiome plays a critical role in human health, mediating the host's physiological functions related to nutrition, barrier function, and immunity (Dai et al., 2015; Feng et al., 2018; Pang et al., 2018; Viggiano et al., 2015). Because microbiomes are very adaptable, they are susceptible to many host factors, including genetics, age, diet, stress, and disease conditions (Horne et al., 2019; Miro-Blanch and Yanes, 2019). When microbiome dysbiosis occurs, the biological balance is broken, provoking host inflammation, immune disorders, metabolic disorders, and other pathological conditions (James et al., 2011; Xian-Qian et al., 2018). Recently, more and more studies have focused on the mechanisms by which the microbiome influences human health and disease, suggesting that microRNA (miRNA) could play a critical role in human–microbiome interactions.

miRNAs are small non-coding RNAs about 22 nucleotides in length that regulate target gene expression (David, 2004). First discovered in nematodes, they have since been identified in many forms of life, including viruses, plants, and animals (Horvitz and Sulston, 1980; Peter et al., 2008; Weronika et al., 2022). By binding the 3’ UTR of target genes, miRNAs can inhibit the process of mRNA translation or accelerate mRNA degradation, ultimately regulating cell development, proliferation, and apoptosis (Marc and Nahum, 2012; TX and ME, 2018). Numerous studies have shown that miRNAs have a role in the onset and progression of illness, and miRNAs have been identified as diagnostic biomarkers and therapeutic targets for a wide range of disorders (Rashid et al., 2020; Pavithra et al., 2021). Studies in the past several years have uncovered interactions between miRNAs and the microbiome that modulate host health and diseases.

In 2011, Dalmaso et al. (2011) discovered nine miRNAs differently expressed in the ileum and the colon from colonized mice that were lacking in germ-free mice. Interestingly, subsequent research has shown that miRNAs generated from dietary supplements may stimulate host gene expression, hence influencing the host–microbiota interplay; however, few are revealed about this process’s mechanism (Gupta et al., 2015; Yi and Kim, 2021). In 2016, Liu et al. (2016) demonstrated that host fecal miRNAs may be able to alter bacterial composition by targeting bacterial genes selectively; this finding was a crucial milestone in understanding the mechanism of the interaction between the microbiome and miRNA. Dysregulation of the symbiosis between the miRNA and the microbiota is linked with a range of diseases, which include inflammatory bowel disease (IBD), colon cancer, and neurological disorders (Ragusa et al., 2020; Cao et al., 2021; Casado-Bedmar and Viennois, 2021). Recently, miRNA–microbiome interplay has become a research hotspot and the focus of many reviews (Jiayi et al., 2019; Deepansh et al., 2021), but comprehensive and visual reviews in this field are limited.

Bibliometric analysis is a statistical method that can be used for both qualitative and quantitative analysis and the evaluation of emerging trends in scientific research (Xiuqing et al., 2021). Despite the rapid growth in miRNA–microbiome interaction research over the past decade, no bibliometric analysis has been published in this field. Using the Web of Science Core Collection (WoSCC) database, we identified miRNA–microbiome-related studies published from 2011 to 2021. We used the R package bibliometrix and VOSviewer to visualize the global research status, hotspots, and trends in the area of miRNA–microbiome interaction. Furthermore, we searched for potential diagnostic biomarkers and therapies for various diseases, aiming to provide insight into accessible clinical applications of miRNA–microbiome interplay.

2 Methods

2.1 Data source and search strategy

All of the data were obtained from the WoSCC database, which includes high-quality scholarly peer-reviewed literature published worldwide and commonly used in bibliometrics (Mathew et al., 2008). Considering database renewal, literature retrieval was conducted on 6 March 2022. The search terms were "miRNA," "microRNA," "miRNAs," "microbiome," "microbial," "microflora," "microbiota," "probiotic," "microorganism," "Saccharomyces," "Lactobacillus," "Bifidobacterium," and "E. coli". The present analysis was concerned with articles and reviews from 2011 to 2021. Publications irrelevant to the search subject were omitted. After the removal of duplicates, a text file containing the remaining 590 analyzed records was downloaded.

2.2 Bibliometric analysis and visualization

In our study, the distribution of countries/regions, years of publication, and authors were analyzed by using the bibliometrix package in R (version 4.1.2). The fitting polynomial model was employed to better demonstrate the variations in the yearly document quantity. Meanwhile, we used the following indicators to assess publication quality by authors:
Publications, citations, h-index (H), and m-index (M) are used to assess a researcher’s academic contribution and forecast future scientific breakthroughs (Hirsch, 2005). To evaluate the quality of Journals, we also obtained the 2021 impact factor (IF) and JCR division of journals from the WoSCC, which are often regarded as one of the most important indices of the quality and influence of medical journals (Ernesto et al., 2019).

The VOSviewer Version 1.6.18 (Centre for Science and Technology Studies, Leiden University, Leiden, Netherlands) was utilized to map bibliometrics, such as co-authorship analysis of authors/institutions/countries, citation analysis of documents, co-citation analysis of journals/references, and co-occurrence analysis of keywords. The following are the VOSviewer parameters: counting method is full counting; the minimum number of citations per source is 100; visualization weights is citations; normalization is association strength; resolution for clustering is 1.00; the minimum cluster size is one; minimum line strength is 200; and the maximum number of lines is 500. Moreover, keywords plus that occurred more than five times were shown in two visualizations (network, and density) of the co-occurrence analysis in order to discover hot topics in the interplay of microRNA and microbiome.

3 Result

3.1 The trends in global publications

WoSCC was searched for 590 articles relating to the relationship between microRNA and microbiome published between 2011 and 2021. From nine publications (1.53%) in 2011 to 142 publications (24.07%) in 2021, the field’s global publications indicated a robust growth tendency. (Figure 1A). The logistic regression model created a time curve indicating that the discipline is now seeing a large increase in the number of yearly publications. \( R^2 = 0.9813 \) (Figure 1B).

3.2 Distribution of countries and institutions

The contributions of countries to microRNA and microbiome research were assessed and illustrated by Bibliometric in a globe map (Figure 2A). 49 countries and regions in total contributed to publications in this topic. China contributed the greatest number of publications (189, 32.03%), followed by the United States (182, 30.85%), Italy (34, 5.76%), Spain (29, 4.92%), and Canada (29, 4.92%) (Figure 2B). United States studies received the most citations (5,838), followed by those from China (3,662 citations), France (1,253 citations), Spain (1,251 citations), and Japan (860 citations) (Figure 2C). In the co-authorship analysis, 23 countries with more than five publications in the topic were shown (Figure 3A). The United States topped the list of five countries with the highest total link strength (92), followed by China (70), Italy (19), Germany (17), and Australia (13).

There were a total of 1,009 institutions engaged in this area. Shanghai Jiaotong University and University calif Davis contributed the greatest number of publications (11, 1.86%), followed by Huazhong agriculture University (9, 1.53%), Tongji University, Sun yat-sen University, Zhejiang University, and Louisiana state University all followed with eight publications. We examined the co-authorship of 60 institutions with over four publications. The exclusion of fifteen items that were not connected revealed the collaborations of 45 institutions (Figure 3B). Tongji University ranked first among the top five institutions with the strengthest total link (8), followed by Shanghai Jiaotong University (7), Sun yat-sen University (7), Fudan University (7), and Chinese Academy of Science (6).

3.3 Analysis of journals and research areas

590 articles altogether were published in 336 journals. Table 1 lists the 10 most popular journals for studies on microRNA and microbiome. International Journal of Molecular Sciences (20 records, 3.39%) had the most publications, followed by
Frontiers in Microbiology (15, 2.54%), Scientific Reports (13, 2.20%), Plos One (10, 1.69%), and Frontiers in Immunology (10, 1.69%). We investigated 71 journals for all papers co-cited in more than 100 publications (Figure 4). Table 1 also displays the top ten cited journals for relevant articles. The journal with the most citations was Plos One (1,462 citations), followed by Nature (1,026 citations), Proceedings of the National Academy of Sciences (PNAS) (902 citations), Cell (894 citations), and Science (699 citations). In all, 54 research areas were used to classify publications. Biochemistry and Molecular Biology was the field with the highest representation (67, 11.36%), followed by Microbiology (49, 8.30%), Pharmacology and Pharmacy (44, 7.46%), Gastroenterology and Hepatology (44, 7.46%), Immunology (36, 6.10%) and Multidisciplinary Sciences (36, 6.10%) (Table 2).

3.4 Analysis of authors

According to the number of publications, Yu AM. was the most prolific author with 10 publications (1.69% of all publications), followed by Tu M. J. (8, 1.36%), Lukiw W. J. (7, 1.19%), Guan L. L. (6, 1.02%) and Dalmasso G. (6, 1.02%) (Figure 5B). According to authors’ citations analysis, Darfeuille M. A. ranked first (789 citations), followed by Dalmasso G. (546 citations), Cerrada E. (455 citations), Dieste A.P. (455 citations), Marmol I. (455 citations), Sanchez-De-Diego C. (455 citations), and Yoldi, M. J. R. (455 citations) (Figure 5C). Publications from Yu AM. earned the highest h-index (10), followed by that from Tu M. J. (8), Lukiw W. J. (7), Cryan J. F. (6), Dinan T. G. (6), Garcia F. (6) and Zhang Y. (6) (Figure 5D). The m-index of publications from Yu AM (1.11)
was also ranked first, followed by that from Batra N. (1.00), Cryan JF (1.00), Dinan T.G. (1.00), and Garcia F. (1.00) (Figure 5E). Moreover, 51 authors that were cited in more than 25 citations were analyzed. The top five authors with the highest total link strength were Liu S. R. (1,262), Dalmasso G. (934), Bartel D. P. (784), Xue X. C. (535), and Zhang L. (504) (Figure 5A).

### 3.5 Citation and co-citation analysis

According to the analysis of citation, 70 documents contained more than 50 citations (Figure 6A). The top 10 documents with the most citations are shown in Table 3. There were 455 citations for “Colorectal
Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer (Marmol et al., 2017), followed by "A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn’s disease" (Brest et al., 2011), with 403 citations. The article with the third-highest amount of citations was "Human
Mesenchymal Stem Cell Microvesicles for Treatment of *E. coli* Endotoxin-Induced Acute Lung Injury in Mice (Zhu et al., 2014), with 403 citations too. In addition, we analyzed 27 references that were co-cited in excess of 20 times (Figure 6B). And the top three references with the largest number of citations were published by Liu S. R., (2016, *Cell Host and Microbe*; 106 citations), Bartel D. P., (2004, *Cell*; 53 citations), and Dalmasso G., (2011, *Plos One*; 53 citations).
3.6 Co-occurrence and cluster analysis of keywords

A total of 195 keywords that were discovered to have appeared more than five times were analyzed (Figure 7A). The five keywords with the highest frequency were expression (151 occurrences), gut microbiota (99), *E. coli* (68), gene expression (65), and microRNAs (61). Table 4 list the top twenty keywords with the highest frequency. Finally, according to the specific algorithm, they gathered into seven effective clusters corresponding to different colors. (Figure 7B).

![Figure 6](image-url)

**Figure 6**

(A) VOSviewer’s network analysis of documents’ citation with more than 50 citations. (B) VOSviewer’s network analysis of references’ co-citation with more than 20 citations.

| Rank | Title                                                                 | First author/year | Source                                                | Citations |
|------|-----------------------------------------------------------------------|-------------------|-------------------------------------------------------|-----------|
| 1    | Colorectal carcinoma: A general overview and future perspectives in colorectal cancer | Marmol L./2017 | International journal of molecular sciences | 455       |
| 2    | A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn’s disease | Brest, P./2011 | Nature genetics                                      | 403       |
| 3    | Human mesenchymal stem cell microvesicles for treatment of *E. coli* endotoxin-induced acute lung injury in mice | Zhu, Y. G./2014 | Stem cells                                            | 403       |
| 4    | The host shapes the gut microbiota via fecal microRNA | Liu, S. R./2016 | Cell host and microbe                                 | 342       |
| 5    | *F. nucleatum* increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-kappa B, and upregulating expression of microRNA-21 | Yang, Y. Z./2017 | Gastroenterology                                     | 290       |
| 6    | Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype | Cougnoux, A./2014 | Gut                                                   | 213       |
| 7    | Gut microbiota metabolism of anthocyanin promotes reverse cholesterol transport in mice via Repressing miRNA-10b | Wang, D. L./2012 | Circulation research                                 | 192       |
| 8    | Genome-wide antisense transcription drives mRNA processing in bacteria | Lasa, I./2011 | Proceedings of the National Academy of Sciences of the United States of America | 174       |
| 9    | Mother’s milk: A purposeful contribution to the development of the infant microbiota and immunity | Le Doare, K./2018 | Frontiers in immunology                              | 171       |
| 10   | New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis | Yuan, T./2019 | Redox biology                                        | 161       |

**Table 3** Top ten citation analysis of documents on miRNA-microbiome interaction research.
FIGURE 7
Keyword co-occurrence and cluster analysis. (A) VOSviewer’s network analysis of keywords. Distribution of keywords according to the mean frequency of appearance. (B) The clustering map based on occurrence analysis was divided into seven parts.
TABLE 4 Top twenty occurrence analysis of keywords on miRNA-microbiome interaction research.

| Rank | Keyword                  | Frequency | Total link strength | Rank | Keyword                        | Frequency | Total link strength |
|------|--------------------------|-----------|---------------------|------|--------------------------------|-----------|---------------------|
| 1    | Expression               | 151       | 642                 | 11   | Identification                | 35        | 151                 |
| 2    | Gut microbiota           | 99        | 398                 | 12   | Inflammatory-bowel-disease    | 33        | 150                 |
| 3    | E. coli                  | 68        | 264                 | 13   | Ulcerative-colitis            | 30        | 139                 |
| 4    | Gene expression          | 65        | 256                 | 14   | Colorectal cancer             | 26        | 128                 |
| 5    | MicroRNAs                | 61        | 276                 | 15   | Biomarkers                    | 25        | 125                 |
| 6    | Cells                    | 43        | 201                 | 16   | NF-kappa-b                    | 25        | 116                 |
| 7    | Activation               | 41        | 198                 | 17   | Proliferation                 | 24        | 122                 |
| 8    | Inflammation             | 40        | 184                 | 18   | Epithelial-cells              | 22        | 104                 |
| 9    | Cancer                   | 37        | 186                 | 19   | Mice                          | 22        | 102                 |
| 10   | Disease                  | 36        | 146                 | 20   | Association                   | 21        | 106                 |

FIGURE 8
The mechanisms of interplay between miRNA and the microbiome. (A) Host-derived miRNA influences microbiota. Mature miRNAs from intestinal epithelial cells can enter microbiota in the form of fecal miRNA or exosomal miRNA. By regulating gene transcription in microbiota, miRNA affects microbial growth, thereby shaping the microbiota. (B) Microbiota influences host miRNA. Microbiota and microbiota-derived metabolites regulate miRNA expression, possibly through toll-like receptor/Myd88-dependent pathways. Moreover, microbiota-derived extracellular vesicle can modulate gut barrier function and the immune response directly.
4 Discussion

4.1 General trends

This study used bibliometric analysis and network visualization to conduct a comprehensive review of research progress on the interaction between miRNA and the microbiome, identifying hot topics within this field and predicting potential directions for future research.

590 articles and reviews spanning 2011–2021 were retrieved. The polynomial-fitting curve showed an overall upward trend for the number of annual publications; 79% of all identified contributions were published in the latter half of the study period. Furthermore, 142 studies were published in 2021, and the curve predicted that more than 200 studies will be published in 2023; this indicates strong growth in the annual publication output in the field.

A visual examination of the distribution of countries and institutions revealed that the United States contributed the largest number of citations and had the greatest number of co-authors, indicating that the United States is the epicenter of research on the interplay between miRNA and the microbiome. China had the greatest number of publications and the second-most citations, indicating that China has made a significant impact on the field. Moreover, China and the United States had strong cooperative relations. Shanghai Jiaotong University and the University of California Davis were the most productive institutions, and they focused on producing miRNA pharmaceuticals for cancer treatment by in vivo fermentation and identifying the mechanism of miRNA–microbiome interaction (Wang et al., 2015; Yang et al., 2017; Ho et al., 2018; Zhu et al., 2020). A paper published in the International Journal of Molecular Sciences had the highest number of citations, and this journal also had the highest number of records. The journals with the highest number of records and citations may be prioritized when the highest number of records. The journals with the highest number of records and citations may be prioritized when

4.2 Influential authors and studies

The h-index was used to assess the scientific research output and citation effect of researchers, while the m-index was intended to ease comparisons across researchers with varied academic careers. Yu A. M et al. (2019) had the largest number of publications and was the top-ranked author according to the h-index and m-index, indicating that he was a leader in terms of academic influence in the area of miRNA–microbiome research. Yu et al. (2020) have focused on developing novel approaches for the efficient production of non-coding RNAs using in vivo fermentation for targeted cancer treatment. They produced hsa-miR-27b, miR-27b-3p, and miR-328-3p in E. coli using recombinant RNA technology, providing a basis for future research on novel pharmaceuticals based on miRNA produced via in vivo fermentation. Liu et al. (2016) had the largest number of co-citations, indicating that he has played a pioneering role in miRNA–microbiome research. He identified that fecal miRNA from the host could enter the bacteria, affecting bacteria gene transcription and growth. Furthermore, Liu et al. (2019) revealed that fecal miRNA transplantation might aid in the restoration of gut microbiota and thus may be applied for clinical therapeutic. Darfeuille M. A. had the highest number of citations (789) and focused on susceptibility genes associated with autophagy in the etiology of Crohn’s disease and their intricate interaction with the gut microbiota (Brest et al., 2011; Lapaquette et al., 2012). These articles suggest that miRNAs and gut microbiota are likely to become physiological or pathological diagnostic markers for intestinal diseases in clinical practice.

We identified 70 documents with more than 50 citations. The records with the three highest numbers of citations focused on the effects of miRNA–microbiome interplay on different diseases. The authors of these papers observed that miRNA–microbiome interactions impacted the regulation of host gene expression involved in colorectal cancer, IBD, and acute lung injury through several mechanisms, including downregulation of autophagy-related proteins, suppression of inflammatory cytokine and chemokine secretion, and alteration of the abundance of microbiome metabolites. The reference with the most co-citations was published by Liu et al. (2016) in Cell Host & Microbe. The authors demonstrated that gut-derived miRNAs were involved in bidirectional interspecies gene regulation that contributed to the makeup of gut microbiota. In recent years, the references with the highest citation frequencies have focused on gene engineering (Yuan et al., 2018), targeted therapy (Rajesh and Frank, 2017), and tumors (Hu et al., 2015). The groundbreaking findings of the top authors and studies in the field of miRNA–microbiome interplay indicate that research has made several breakthroughs in the diagnosis and treatment of cancer by elucidating the mechanisms of miRNA–microbiome interactions.

4.3 Hotspots and frontiers

Keywords can be used to present and summarize the central argument and core content of the literature. This study used keyword co-occurrence analysis to explore the distribution and development of research hotspots in the field (Jie et al., 2021). The keywords that appeared more than 20 times, including
“miRNA” and “gut microbiota,” are shown in Table 4. A clustering analysis was performed on the basis of keyword co-occurrence analysis to create a clustering map, which was divided into the following areas: physiological function (gene expression, autophagy, and apoptosis), diseases (cancer, IBD, et al.), and pharmacology (probiotic, in vivo, and E. coli).

### 4.3.1 miRNA–microbiome interaction in regulating host gene expression

Studies have shown that miRNAs are implicated in microbiota-mediated control of host gene expression (Mody et al., 2021). Dalmasso and his team identified nine miRNAs in the ileum and colon of colonized mice that were expressed differently from those found in germ-free mice (Dalmasso et al., 2011). Experiments In vitro indicated that the downregulation of one of these miRNAs, mmu-mir-665, upregulated the expression of the target gene Abcc3 during colonization, suggesting that miRNA may be implicated in gut microbiota-regulated changes in host gene expression (Dalmasso et al., 2011). Other studies have found that the gut microbiota can modulate host immune responses via miRNAs. For example, bacteria were shown to inhibit the production of miR-10a in dendritic cells through TLR–TLR ligand interactions mediated by a MyD88-dependent mechanism (Xue et al., 2011). miR-155, which is involved in TLR activation via bacteria-derived lipopolysaccharides, was shown to activate tumor necrosis factor (TNF)-α and interleukin (IL)-6 and regulate suppressor of cytokine signaling 1 (SOCS1) on dendritic cells, thus playing a role in adaptive immune responses (Esmerina et al., 2007; Naqvi et al., 2014). In addition, bacteria can secrete extracellular vesicles that carry extracellular miRNAs; these vesicles participate in intercellular communication to reach remote target cells (Yu et al., 2019; Badi et al., 2020; Stanton, 2021). For example, the probiotic E. coli Nissle 1917 strain produces outer-membrane vesicles that control the expression of the ZO-1 and ZO-2 tight junction proteins, enhancing intestinal immune regulation and barrier function (Veltman et al., 2012; Sabharwal et al., 2016).

Conversely, host miRNA may also regulate gut microbiota colonization and gene expression. In 2016, Liu et al. (2016) reported that fecal miRNAs may influence the composition of the gut microbiota. First, they used 16sRNA sequencing to identify the fecal bacteria of wild-type mice and Dicer1ΔIEC mice, which revealed substantial variations between the two groups in the species and abundance of the fecal bacteria. Subsequent in vitro studies found that miR-515-5p and miR-1226-5p promoted the growth of F. nucleatum and E. coli, respectively, demonstrating that miRNAs directly affect bacterial growth. Further investigation revealed that fecal miRNA could affect intestinal microorganisms. The fecal miRNA of wild-type mice was extracted and transplanted into intestinal epithelial cell (IEC) miRNA-deficient (Dicer1ΔIEC) mice, which exhibit dysfunctional gut microbiota (Moloney et al., 2018; Lei et al., 2019; Bi et al., 2020; Cheng et al., 2021). Interestingly, the gut microbiome of Dicer1ΔIEC mice was restored after transplantation, with species composition and abundance similar to those of the microbiome of wild-type mice (Monaghan et al., 2021; Zhang et al., 2021). Therefore, fecal miRNA transplantation appears to have therapeutic potential. In addition, recent findings have demonstrated that host-secreted miRNAs could regulate gene transcripts in bacteria (such as F. nucleatum and E. coli) and affect their growth, supporting the above research results. Figure 8 showed the mechanisms of interplay between miRNA and the microbiome (Liu et al., 2016; Yun et al., 2018; Santos et al., 2020). In brief, these studies demonstrate that bidirectional modulation between the gut microbiota and miRNAs regulates host gene expression through various pathophysiologic pathways and microbiome-derived metabolites (Table 5).

### 4.3.2 Interplay between miRNA and the microbiome in diseases

#### 4.3.2.1 Colorectal cancer

Colorectal cancer (CRC) ranks as the third-leading cause of cancer-related death worldwide and represents approximately 10% of all tumors every year (Marmol et al., 2017). Multiple studies have established that an imbalance in the gut microbiota contributes to tumor cells invasion and metastasis (Tania et al., 2020; Jaeho and Heung, 2021) and that miRNAs can intervene in the genesis of CRC by mediating the microbiome (He et al., 2017; Yuan and Subramanian, 2019; Peruhova et al., 2020). Patients with early-stage CRC showed a significant increase in F. nucleatum, Bacteroides fragilis, E. coli, and Enterococcus faecalis, accompanied by increased levels of inflammatory factors and macrophage inflammatory protein 3A (MIP3A) in the serum (Aleksandar et al., 2013; Yuan et al., 2018). Additionally, miR-20a, miR-21, miR-96, miR-182, miR-183, and miR-7974 were dramatically overexpressed in cancerous tissues, suggesting that cancer-specific miRNAs are modulated in the early stages of the disease (Yuan et al., 2018). Recently, F. nucleatum was found to upregulate the expression of miR-21, initiating TLR4–MyD88 activation and augmenting CRC cell proliferation (Yang et al., 2017). In addition, the gut microbiota plays a critical role in the regulation of cancer metastasis through the IL11/circular RNA/miRNA/SOX9 axis (Zhu et al., 2020). Thus, miRNA–microbiome interaction plays a critical role in CRC development, and F. nucleatum miR-21 is suggested to be a promising diagnostic and prognostic biomarker for CRC.

Further research found that both endogenous and exogenous miR-139-5p may limit the proliferation of F. nucleatum-related CRC by provoking tumor-specific proteins, such as c-Myc and cyclin D1 (Zhao et al., 2020), demonstrating the potential therapeutic value of endogenous or exogenous miRNA in CRC. Furthermore, diet and metabolism, which affect the gut microbiota composition, also impact the development of CRC disease (Rajoka et al., 2018; Chen et al., 2021). Butyrate, a
bacterial-derived metabolite, can reduce the expression levels of miR-92a, consequently inhibiting the proliferation of colon cancer cells and stimulating apoptosis (Hu et al., 2015; Ali et al., 2021). Together, these results indicate new diagnostic and prognostic biomarkers, and therapeutic targets for CRC patients.

4.3.2.2 Inflammatory bowel disease

IBD is a term used to describe chronic inflammatory disorders of the gastrointestinal tract, including Crohn’s disease (CD) and ulcerative colitis (UC). Recently, a growing body of evidence has suggested that inflammation is connected to the overexpression of miRNA-21, which is positively correlated with histologically assessed disease severity (Dai et al., 2015; Mallet et al., 2021; Nivedita et al., 2022; Xiaoran et al., 2022). Moreover, Johnston et al. used 16s rRNA sequencing analysis to confirm altered microbial composition in miR-21−/− colitis model mice, including an increase in the number of *Firmicutes* and a decrease in the number of the phylum *Bacteroidetes* (Johnston et al., 2018). This suggests that miR-21 affects the etiology of intestinal inflammation by altering intestinal microbiota composition (Joana et al., 2018).

In patients with IBD, the expression of miR-10a is negatively regulated by microbiome via a MyD88-dependent pathway, promoting intestinal homeostasis (Xue et al., 2011). Other inflammatory pathways have also been reported in the past decade. IBD-associated adherent invasive *E. coli* (AIEC) has been linked to IBD pathology as a cause or contributing factor (Carolina et al., 2017). AIEC-induced IBD upregulated the levels of miR-30C and miR-130A by activating the NF-kb pathway, reducing the expression of proteins related to autophagy (Larabi et al., 2020). Moreover, the miRNA let-7b was found to effectively reduce proinflammatory cytokines in AIEC-infected mice by regulating TLR-4 expression, suggesting that let-7b is a prospective therapeutic target for IBD, especially AIEC-induced IBD (Guo et al., 2018). Recently, exosomal miR-181a from mesenchymal stem cells was demonstrated to alleviate inflammation and promote intestinal barrier function by decreasing TNF-α, IL-6, IL-1β, IL-17, and IL-18 levels; increasing claudin-1 and ZO-1 levels; and affecting the gut microbiota (Gu et al., 2021). This indicates that miR-181a may exhibit the potential to treat dysfunction of the intestinal mucosal barrier.

In addition, the probiotics *Lactobacillus fermentum*, *Lactobacillus salivarius*, and *E. coli* Nissle 1917 were shown to modulate miRNAs (miR-143, miR-150, miR-223, and miR-375) in a colitis mouse model and reverse the disruption of the intestinal immune barrier (Rodriguez-Nogales et al., 2017; Rodriguez-Nogales et al., 2018a; Rodriguez-Nogales et al., 2018b). Thus, miRNA–microbiome interactions hold potential for effective diagnostic, preventive, and therapeutic methods in IBD.

4.3.2.3 Neurological disorders

Gut microbes are key signaling components in the bidirectional communication between the gut and the brain (Emeran et al., 2015). Recent research described the critical roles of miRNAs in regulating gut–brain axis functions.
Using in silico target screening, Hewel et al. identified over 300 commonly dysregulated miRNAs involved in bacterial pathways connected to AD and PD, including hsa-miR-1183, hsa-miR-3916, hsa-miR-1538, hsa-miR-3180-5p, hsa-miR-1248, hsa-miR-4767, hsa-miR-1301-3p, hsa-miR-378c, hsa-miR-671-5p, and hsa-miR-939-5p (Hewel et al., 2019). Alternatively, miRNA–microbiome interactions may impact different parts of the brain related to behavior and cognition. In germ-free mice, 134 dysregulated miRNAs were detected in the amygdala and the prefrontal cortex; dysfunction in these brain regions can lead to fear- and anxiety-like disorders. However, the increased expression of miR-294-5p in the hippocampus of germ-free mice normalized upon recolonization (Hoban et al., 2017). This miRNA targets and regulates the kynurenine metabolic pathway, demonstrating the crucial role of miRNA–microbiome interaction in neurological disorders and presenting an opportunity for the development of potential treatment (Moloney et al., 2017).

A recent study reported that oral administration of Lactobacillus could reduce the expression of miR-155 and increase the expression of miR-25 by reversing the effect of cuprizone and alleviating demyelinating symptoms in MS (Digehsara et al., 2021). Together, these studies suggest that probiotics and miRNAs have the potential to improve the prevention, treatment, and prognosis of neurological diseases.

### 4.3.3 Pharmacology of miRNA–microbiome interplay

Because of the role of miRNA–microbiome interplay in modulating physiological and pathological conditions, therapeutic strategies such as dietary change, probiotic supplementation, fecal transplantation, and miRNA drug administration are promising (Masterson et al., 2020; Mallet et al., 2021; Mao et al., 2021; Monaghan et al., 2021). In pharmacology, probiotics (such as Bifidobacterium and Lactobacillus) have been widely used to treat diseases such as cancer, neurological disorders, and IBD (Ahmed et al., 2019; Hasan and Yang, 2019; Heydari et al., 2019). However, miRNA drugs have not been developed for clinical use because they are endogenous, have multiple targets, and show poor biological stability (Aditya et al., 2017; Schmidt, 2017; Moloney et al., 2017). The strategies currently used to manipulate miRNAs typically substitute or upregulate the expression of targeted miRNA or downregulate the expression of mature miRNAs to inhibit them. Studies have revealed that in vitro technologies, such as miRNA mimics, agomirs, precursors containing stem-loops, and viral vector constructs, could upregulate gene expression (Bianca et al., 2015; Sarah and Gyorgy, 2020), whereas anti-miRNA oligonucleotides, antagonirs, and miRNA sponges could downregulate gene expression (Kesley et al., 2015; Johnston et al., 2018). Because of the problems that arise when miRNA drugs are transported from the in vitro environment to target cells (degradation, off-target effects, and toxicity), researchers have begun to produce miRNA drugs using in vivo fermentation.

Yu A. M. et al. (2019) produced a variety of RNA vectors that can be expressed as endogenous molecules. These molecules continuously accumulate and express in vivo and then form recombinant RNA molecules in bacteria to regulate the expression of target genes (Li et al., 2014; Li et al., 2015). This fermentation technology is a consistent, efficient, and cost-effective method to produce various biological RNA reagents (Zhang et al., 2018; Yu et al., 2020). In addition, they used fermentation technology to produce bioengineered RNA agents. In human tumor LS-180 cells, BERA/mir-27b-3p was processed into mature mir-27b-3p, which made the tumor cells sensitive to chemotherapeutic drugs (Li et al., 2019). In addition, Sun et al. (2017) developed a bacteriophage PP7 virus-like particle (VLP)-based delivery system without infectious, replicative, or cytotoxic effects. They found that recombinant PP7 VLPs carrying a cell-penetrating peptide (CPP) and miRNA were more efficiently expressed in E. coli than other miRNA delivery methods; therefore, they could be used as an effective and stable delivery vector of miRNA. Overall, in vivo fermentation technology has the potential to be used for genomic diagnosis and treatment and could be validated for clinical use in the future.

### 4.4 Limitations

Although we followed bibliometric principles and comprehensive analysis strategies, our research has several limitations. First, our study is restricted to the WoSCC database, resulting in the loss of any studies not included in the WoSCC. Future studies utilizing more databases (such as Scopus and Pubmed) with wider coverage are strongly encouraged. Second, although the study period of 2011–2021 reflects the major research breakthroughs and hotspots, some original papers that made groundbreaking contributions to this field, along with newly published papers, may have been overlooked. Third, all information was extracted by the R package bibliometrix and VOSviewer, which may be biased by the results of other bibliometric tools.

### 5 Conclusion

This bibliometric study revealed that the number of publications in the field of miRNA–microbiome research in the past decade has increased continuously and rapidly. China
was a major producer of studies, and the USA had a great influence in this field. The interaction between the microbiome and miRNA regulates host gene expression and is implicated in the pathogenesis of many groups of diseases, such as cancer (colorectal cancer, et al.), IBD (CD and UC), and neurological disorders (anxiety, PD, AD, et al.), and this interaction has thus become a research hotspot. The literature suggests that miR-21, miR-155, miR-146a, E. coli, Bifidobacterium, F. nucleatum, and butyric acid have the potential to improve disease diagnosis, treatment, and prognosis. Our results indicate that future research may explore miRNA drugs produced by in vivo fermentation, a technology that can greatly increase the stability and reduce the degradation of miRNA.

Data availability statement

The original contributions presented in the study are included in the article/supplementary materials. The study data supporting the conclusions of this article will be shared openly, without undue reservation.

Author contributions

All authors have full access to all data in this study and are responsible for the completeness of the data. YL and MC contributed to concept and design the study. X-YY, Y-QL, J-PY, WZ, and M-HX acquired, verified, and interpreted study data. Y-QL performed statistical analysis. X-YY and J-PY wrote the first draft of the manuscript. All authors read and revised the manuscript to reach a consensus.

Funding

YL received one grant (No. 82074554) from the National Natural Science Foundation of China and another grant (No. 2021Y0197) from the Foundation of the Science and Technology Department of Sichuan Province, China.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Aditya, G., Sheema, K., Bilal, B. H., Stephen, W. B., Murali, M. Y., Subbhash, C. C., et al. (2017). miRNA nanotherapeutics for cancer. Drug Discov. Today 22 (2), 43244–432432. doi:10.1016/j.drudis.2016.10.014

Ahmed, B., Raul, A., Tareen, K. Z., Akash, M. S. H., Muhammad, S. A., Irfan, M., et al. (2019). Contemporaneous evidence on the dynamic role of probiotics in liver diseases. Pak. J. Pharm. Sci. 32 (6), 2759–2764.

Aleksandar, D. K., Eunyoung, C., Lauren, R., Jonathan, N. G., Carey, A. G., Monia, M., et al. (2015). Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the Cell Host Microbe 14 (2), 207207–215215. doi:10.1016/j.chom.2013.07.007

Ali, S. R., Orang, A., Marri, S., McKinnon, R. A., Meech, R., and Michael, M. Z. (2021). Integrative transcriptomic network analysis of butyrate treated colorectal cancer cells. Cancers 13 (4), 636. doi:10.3390/cancers13040636

Badi, S. A., Bruno, S. P., Moshari, A., Tarashi, S., Siadat, S. D., and Masotti, A. (2020). Small RNAs in outer membrane vesicles and their function in host-microbe interactions. Front. Microbiol. 11, 1209. doi:10.3389/fmicb.2020.01209

Bi, K. F., Zhang, X. J., Chen, W. B., and Diao, H. Y. (2020). MicroRNAs regulate intestinal immunity and gut microbiota for gastrointestinal health. A comprehensive review. Genes 11 (9), E1075. doi:10.3390/genes11091075

Bianca, C. B., Jenny, Y. O., Ruby, C. L., and Julie, R. M. (2015). miRNA therapeutics: a new class of drugs with potential therapeutic applications. Future Med. Chem. 7 (13), 17711771–17921792. doi:10.4155/fmc.15.107

Breit, P., Laparquette, P., Soudi, M., Lebring, K., Cesaro, A., Vouret-Craviari, V., et al. (2011). A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn’s disease. Nat. Genet. 43 (3), 242–245. doi:10.1038/ng.762

Cao, Y. Y., Wang, Z. H., Yan, Y. Q., Ji, I. H., He, J., Xuan, B. Q., et al. (2021). Enterotoxigenic Bacteroides fragilis promotes intestinal inflammation and malignancy by inhibiting exosome-packaged miR-149-3p. Gastroenterology 161(5), 1552–1566. doi:10.1053/j.gastro.2021.08.003

Carolina, P., Caroline, C., Zihlu, X., Joana, T., Gwladys, S., Robert, H., et al. (2017). Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut 67 (3), 574–578. doi:10.1136/gutjnl-2017-314903

Casado-Bedmar, M., and Viennois, E. (2021). MicroRNA and gut microbiota: Tiny but mighty novel insights into their cross-talk in inflammatory bowel disease pathogenesis and therapeutics. J. Crohns Colitis 14, 992–1005. doi:10.1093/jcco/jyab223

Chen, Y. S., Ji, J., Menon, R., Jayaraman, A., Lee, K., Huang, Y., et al. (2021). Dietary spinach reshapes the gut microbiome in an apc-mutant genetic background: mechanistic insights from integrated omics. Gut Microbes 13 (3), 1972576. doi:10.1080/19490976.2021.1972576

Cheng, L. Q., Kazmierczak, D., Norenbarg, H., Hamsten, M., Fransson, E., Schuppe-Koistinen, I., et al. (2021). A MicroRNA gene panel predicts the vaginal microbiota composition. Mystems 6 (3), e00175. doi:10.1128/mSystems.00175-21

Dai, X., Chen, X., Chen, Q., Shi, L., Liang, H. W., Zhou, Z., et al. (2015). MicroRNA-193a-3p reduces intestinal inflammation in response to microbiota via down-regulation of colonic PepT1. J. Biol. Chem. 290 (26), 16099–16115. doi:10.1074/jbc.M115.659318

Dalmasso, G., Hang, T. T. N., Yan, Y. T., Larou, H., Charania, M. A., Ayyadurai, S., et al. (2011). Microbiota modulate host gene expression via MicroRNAs. PLoS One 6 (4), e19293. doi:10.1371/journal.pone.0019293
cluster transcription in human colon cancer cells. Mol. Cancer 14, 180. doi: 10.1186/s12935-015-0450-x

Jaeho, K., and Heung, K. L. (2021). The role of gut microbiota in modulating tumor growth and anticancer agent. Mol. Cells 44 (5), 35636–362362. doi:10.14348/molcells.2021.0302

James, M. K., Ara, W. D., and Jeramy, K. N. (2011). Gut microbiome-host interactions in health and disease. Genome Med. 3 (3), 14. doi:10.1186/gm228

Jiayi, D., Jesse, W. T., and Lu, L. F. (2019). miRNA-microRNA interaction in gut homeostasis and colorectal cancer. Trends Cancer 5 (11), 66666–66966. doi:10.1016/j.trecan.2019.08.003

Jie, Z., Luxia, S., Layan, X., Xuyan, F., Tong, W., Wende, T., et al. (2021). Knowledge domain and emerging trends in ferroptosis research: A bibliometric and. Front. Oncol. 11, 686726. doi:10.3389/fonc.2021.686726

Joana, F. L., Laura, C., Ceu, F., Carla, O., and Nuno, F. A. (2018). - anti-miRNA oligonucleotides: A comprehensive guide for design. RNA Biol. 15 (3), 338338–352352. doi:10.3727/154762618X1445599

Johnston, D. G. W., Williams, M. A., Thaiss, C. A., Cabrera-Rubio, R., Ravendeur, M., McEntee, C., et al. (2018). Loss of MicroRNA-21 influences the gut microbiota, causing reduced susceptibility in a murine model of colitis. J. Crohns Colitis 12 (7), 835–848. doi:10.1016/j.crohcs.2018.09.038

Kathryn, P., and James, V. (2012). Human microbiome in health and disease. Annu. Rev. Pathol. 7, 999–122122. doi:10.1146/annurev-pathol-011811-132421

Kesley, B., Chiostrophor, N., and Craig, L. D. (2015). MiRNA inhibition in tissue engineering and regenerative medicine. Adv. Drug Dev. Res. 88, 123123–137137. doi:10.1161/ahdar.2014.12.006

Lapaquette, B., Prett, B., Hofman, P., and Darfeuille-Michaud, A. (2012). Etiology of Crohn’s disease: many roads lead to autophagy. J. Med. Mat. 90 (9), 987–996. doi:10.1007/s10909-012-0934-8

Larabi, A., Dalmaso, G., Delmas, J., Barnich, N., and Nguyen, H. T. T. (2020). Eosinocytes transfer miRNAs from cell-to-cell to inhibit autophagy during infection with Crohn’s disease-associated adherent-invasive E. coli induced intestinal inflammation via modulating Toll-Like Receptor 4 in intestine epithelial cells. Biochem. Pharmacol. 156, 196–203. doi:10.1016/j.bcp.2018.08.029

Gupta, I., Sehgal, R., Kanwar, R. K., Punj, V., and Kanwar, J. R. (2015). Nanocapsules loaded with iron-saturated bovine lactoferrin have antimicrobial therapeutic potential and maintain calcium, zinc and iron metabolism. Nanomedicine 10 (8), 1289–1314. doi:10.2217/nnm.14.209

Hasan, N., and Yang, H. Y. (2019). Factors affecting the composition of the gut microbiota, and its modulation. peerJ 7, e7502. doi:10.7717/peerJ.7502

He, C., Yu, T. M., Shi, Y., Ma, C. Y., Yang, W. J., Fang, L. L., et al. (2017). Common mirRNA patterns of Alzheimer’s disease and Parkinsson’s disease and their putative impact on commensal gut microbiota. Front. Neurosci. 11, 133. doi:10.3389/fnins.2019.00113

Hewel, C., Kaiser, J., Wierczeiko, A., Jan, L. K., Reinhardt, C., Endres, K., et al. (2021). Colorectal carcinoma: A general Overview and future Perspectives in colorectal cancer therapy. Expert Opin. Drug Deliv. 18 (12), 1689–1702. doi:10.1080/17425247.2020.1814732

Heydari, Z., Rahaie, M., Alizadeh, A. M., Agah, S., Khalighfard, S., and Bahmani, H. (2015). Gut/brain axis and the microbiota. Expert Rev. Food Sci. Technol. 16 (3), 1795. doi:10.1586/17444715.16.3.1795

Hiroyuki, S., Sakanishi, M., Nakamura, Y., and Saito, H. (2016). Polyphenol-enriched blueberry preparation controls breast cancer stem cells by targeting PDX1 and miR-145. Molecules 21 (4), 922. doi:10.3390/molecules21040922

Hohmann, T. J., and Craparo, R. M. (2016). The role of gut microbiota in modulating tumor growth and anticancer agent. Mol. Cancer 15 (6), 1795. doi:10.1186/s12943-016-0444-3

Hohmann, T. J., and Craparo, R. M. (2016). The role of gut microbiota in modulating tumor growth and anticancer agent. Mol. Cancer 15 (6), 1795. doi:10.1186/s12943-016-0444-3

Hof, P. Y., Duan, Z. J., Batra, N., Nek, J., Lu, M. J., Qiu, J. X., et al. (2018). Bioengineered noncoding RNAs selectively change cellular miRNA profiles for cancer therapy. J. Pharmacol. Exp. Ther. 365 (3), 494–506. doi:10.1124/jpet.118.247775

Hoban, A. E., Stillling, R. M., Moloney, G. M., Moloney, R. D., Shanahan, F., Dinan, T. G., et al. (2017). Microbial regulation of microRNA expression in the amygdala and prefrontal cortex. Microbiome 5, 102. doi:10.1186/s40164-017-0321-3

Horne, R., St Pierre, J., Odde, S., Surette, M., and Foster, J. A. (2019). Microbe and host interaction in gastrointestinal homeostasis. Psychopharmacology 236 (5), 1623–1640. doi:10.1007/s00213-019-05218-y

Hohr, H. V., and Sulston, J. E. (1980). Isolation and genetic characterization of cell-lineage mutants of the nematode. - Genetics 96 (2), 453455–454454. doi:10.1093/ genetics/96.2.435

Hu, S. E., Liu, J., Chang, E. B., Wang, J. Y., and Raufman, J. P. (2015). Butyrate inhibits pro-inflammatory miR-92a by diminishing c-Myc-induced miR-17-92a
Mathew, E. F., Elena, P., George, A. M., and Georgios, P. (2008). Comparison of PubMed, Scopus, Web of science, and google scholar: strengths and weakness. FASEB J. 22, 338. doi: 10.1096/fj.07-9492LSF

Mikkel, M., Jaslin, J., Christian, J., Eisd, H., Kim, H., Vibeke, W., et al. (2021). Microbial microRNA expression and age and severity of disease in ulcerative colitis. Aging 13, 6359. doi:10.18632/aging.202715

Miro-Blanch, J., and Yanes, O. (2019). Epigenetic regulation at the interplay between gut microbiota and host metabolism. Front. Genet. 10, 638. doi:10.3389/fgene.2019.00614

Mody, D., Verma, V., and Rani, V. (2021). Modulating host gene expression via gut microbiome-microRNA interplay to treat human diseases. Crit. Rev. Microbiol. 47 (5), 596–611. doi:10.1080/1040841X.2021.1907739

Moloney, G. M., Dinan, T. G., Clarke, G., and Cryan, J. F. (2019). Microbial regulation of microRNA expression in the brain-gut axis. Curr. Opin. Pharmacol. 48, 120–126. doi:10.1016/j.coph.2019.08.005

Moloney, G. M., O’Leary, O. F., Salvo-Romero, E., Desbonnet, L., Shanahan, F., Dinan, T. G., et al. (2017). Microbial regulation of hippocampal miRNA expression: Implications for transcription of kynurenine pathway enzymes. Behav. Brain Res. 334, 50–54. doi:10.1016/j.bbr.2017.07.026

Moloney, G. M., Ysla, M. F., Hoban, A. E., Dinan, T. G., and Cryan, J. F. (2018). Facial microRNAs influence at the host-microbe interface? Benef. Microbes 9 (2), 175–183. doi:10.3920/bm2017.00113

Monaghan, T. M., Seekatz, A. M., Markham, N. O., Yau, T. O., Hatziapostolou, M., Jilani, T., et al. (2021). Fecal microbiota transplantation for recurrent clostridiodes difficile infection associates with functional alterations in circulating microRNAs. Gastroenterology 161 (1), 255–270.e4. doi:10.1053/j.gastro.2020.09.030

Naqvi, A. R., Fordham, J. B., Khan, A., and Nares, S. (2014). MicroRNAs responsive to Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis LPS modulate expression of genes regulating innate immunity in human macrophages. Innate Immun. 20 (5), 540–551. doi:10.1177/1753453114525014

Nivedita, B., Hsu, W., Ganguleo, W., Paul, J. B., and M Firoze, K. (2022). Differential expression of miRNAs in trichloroethene-mediated. Front. Immunol. 13, 868539. doi:10.3389/fimmu.2022.868539

Pang, Y., Yu, B., Shi, Y. C., Deng, L., Xu, C. H., Wu, S. Z., et al. (2018). Alteration of intestinal flora stimulates pulmonary microRNAs to interfere with host antiviral immunity in influenza. Molecules 23 (12), E1351. doi:10.3390/molecules23121351

Pavithra, S., Usha, M., Devi, R., and Ramalingam, B. (2021). Circulating exosomal miR-21 mediates HUVEC proliferation and migration. Front. Mol. Biosci. 8, 611. doi:10.3389/fmolb.2021.00181

Peter, B., Lali, S.-A., Mariannre, B.-R., Patrice, D., Yamamoto, Y. Y., Sieburth, L., et al. (2015). Proteinase K as a TRAP to enable efficient preparation of RNA of high yield from FFPE tissue. J. Histotechnol. 48 (3), 167–172. doi:10.1177/1086291814553932

Pang, P., Yu, B., Shi, Y. C., Deng, L., Xu, C. H., Wu, S. Z., et al. (2018). Facial microRNA expression and gut microbiota composition. J. Nutr. Biochem. 61, 129–139. doi:10.1016/j.jnutbio.2018.08.005

Rodríguez-Nogales, A., Algieri, F., Garrido-Mesa, J., Vezza, T., Urrilla, M. P., Chueca, N., et al. (2018a). The administration of Escherichia coli Nissle 1917 ameliorates development of DSS-induced colitis in mice. Front. Pharmacol. 9, 468. doi:10.3389/fphar.2018.00468

Sabharwal, H., Cichon, C., Schilsgaard, T. A., Sonnenborn, U., and Schmidt, M. A. (2016). Interleukin-8 CXCL1, and MicroRNA miR-146a responses to probiotic Escherichia coli Nissle 1917 and enteropathogenic E. coli in human intestinal epithelial TH4 and monocytic TH1 cells after apical or basolateral infection. Infect. Immun. 84 (9), 2482–2492. doi:10.1128/iai.00402-16

Santos, A. A., Afonso, M. B., Ramiro, R. S., Pires, D., Pimentel, M., Castro, R. E., et al. (2020). Host miRNA-21 promotes liver dysfunction by targeting small intestinal Lactobacillus in mice. Gut Microbes 12 (1), 1. doi:10.1080/19490967.2020.1840766

Sarah, B., and Gyorgy, H. (2020). RNA-based therapeutics: From antisense oligonucleotides to microRNA. Gastroenterology 159, 1190–1198. doi:10.1053/j.gastro.2016.11.018

Schmidt, M. F. (2017). miRNA targeting drugs: The next blockbusters? - Methods Mol. Biol. 1517, 32–22. doi:10.1007/978-1-4939-6563-2_3

Seo, M., and Anderson, G. (2019). Gut-amygala interactions in autism spectrum disorders: Developmental roles via regulating mitochondria, exosomes, immunity and microRNAs. Curr. Pharm. Des. 25 (41), 4344–4356. doi:10.2174/138161282666619110105245

Singh, R., Zogg, H., and Bo, S. (2021). Role of microRNAs in disorders of gut-brain interactions: Clinical insights and therapeutic alternatives. J. Pers. Med. 11 (10), 1021. doi:10.3390/jpm11101021

Stanton, B. A. (2021). Extracellular vesicles and host-pathogen interactions: A review of inter-kingdom signaling by small noncoding RNA. Genes 12 (7), 1010. doi:10.3390/genes12071010

Sun, Y. L., Sun, Y. H., and Zhao, R. L. (2017). Establishment of MicroRNA delivery system by PP7 bacteriophage-like particles carrying cell-penetrating peptide. J. Biotechnol. 214 (2), 242–249. doi:10.1016/j.jbiotec.2017.03.012

Tania, R., Daniele, V., Francesca, F., Michale, M., Sara, B., and Francesca, P. (2020). MicroRNA-derived metabolites in tumor progression and metastasis. Int. J. Mol. Sci. 21 (16), 5786. doi:10.3390/ijms21165786

Takahashi, M., Jilani, T., et al. (2021). Fecal microbiota transplantation for recurrent Clostridium difficile difflamations. Benef. Microbes 12, 1. doi:10.3389/fmicb.2020.1011021

van den Bom, R. W., Po, Y. C., Chen, Q. X., Addepalli, B., Limbach, P. A., Li, M. M., et al. (2015). Bioengineering novel chimeric microRNA-34a for prodrug cancer therapy: Improved target specificity of E. coli Nissle 1917 on TH4 epithelial cells. Int. J. Biochem. Cell Biol. 44 (2), 341–349. doi:10.1016/j.biocel.2011.11.006

Viggianno, D., Ianio, G., Vanella, G., Bibbo, S., Bruno, G., Simeone, G., et al. (2015). Gut barrier in health and disease: focus on childhood. Eur. Rev. Med. Pharmacol. Sci. 19 (6), 1077–1085. doi:10.2174/1389430413666612222222

Wang, W. P., Ho, P. Y., Chen, Q. X., Addepalli, B., Limbach, P. A., Li, M. M., et al. (2015). Bioengineering novel chimeric microRNA-34a for prodrug cancer therapy: High-yield expression and purification, and structural and functional characterization. J. Pharmacol. Exp. Ther. 354 (2), 131–141. doi:10.1124/jpet.115.225631

Wen, M., Jilani, T., et al. (2021). Establishment of MicroRNA delivery system by PP7 bacteriophage-like particles carrying cell-penetrating peptide. J. Biotechnol. 214 (2), 242–249. doi:10.1016/j.jbiotec.2017.03.012

Yan et al. 10.3389/fphar.2022.974775
Yi, D. Y., and Kim, S. Y. (2021). Human breast milk composition and function in human health: From nutritional components to microbe and MicroRNAs. *Nutrients* 13 (9), 3094. doi:10.3390/nu13093094

Yu, A. M., Batra, N., Tu, M. J., and Sweeney, C. (2020). Novel approaches for efficient in vivo fermentation production of noncoding RNAs. *Appl. Microbiol. Biotechnol.* 104 (5), 1927–1937. doi:10.1007/s00253-020-10350-3

Yu, A. M., Jian, C., Yu, A. H., and Tu, M. J. (2019). RNA therapy: Are we using the right molecules? *Pharmacol. Ther.* 196, 91–104. doi:10.1016/j.pharmthera.2018.11.011

Yu, S. R., Zhao, Z. H., Xu, Y. Y., Li, M., and Li, P. (2019). Characterization of three different types of extracellular vesicles and their impact on bacterial growth. *Food Chem.* 272, 372–378. doi:10.1016/j.foodchem.2018.08.059

Yuan, C., Burns, M. B., Subramanian, S., and Blekhman, R. (2018). Interaction between host MicroRNAs and the gut microbiota in colorectal cancer. *Msystems* 3 (3), e00205. doi:10.1128/mSystems.00205-17

Yuan, C., and Subramanian, S. (2019). microRNA-mediated tumor-microbiota metabolic interactions in colorectal cancer. *DNA Cell Biol.* 38 (4), 281–285. doi:10.1089/dna.2018.4579

Yun, T., Yi, R., Mohammed, S., Xin, H., Chao, L., Anil, K., et al. (2018). Plant-derived exosomal MicroRNAs shape the gut microbiota. *Cell Host Microbe* 24 (5), 637–652. doi:10.1016/j.chom.2018.10.001

Zhang, Q. Y., Ho, P. Y., Tu, M. J., Jilek, J. L., Chen, Q. X., Zeng, S., et al. (2018). Lipidation of polyethyleneimine-based polyplex increases serum stability of bioengineered RNAs agents and offers more consistent tumoral gene knockdown in vivo. *Int. J. Pharm.* 547 (1-2), 537–544. doi:10.1016/j.ijpharm.2018.06.026

Zhao, Y. S., Yin, Y. S., Wang, J. C., Battaglia, T., Krautkramer, K., Li, W. V., et al. (2021). Maternal cecal microbiota transfer rescues early-life antibiotic-induced enhancement of type 1 diabetes in mice. *Cell Host Microbe* 29 (8), 1249–1265. doi:10.1016/j.chom.2021.06.014

Zhao, Y. H., and Lukiw, W. J. (2018). Bacteroidetes neurotoxins and inflammatory neurodegeneration. *Mol. Neurobiol.* 55 (12), 9100–9107. doi:10.1007/s12035-018-1101-y

Zhao, Y. Y., Tao, Q. Y., Li, S. Y., Zheng, P. Y., Liu, J. W., and Liang, X. (2020). Both endogenous and exogenous milk-139pSp inhibit Fusobacteria nucleatum-related colorectal cancer development. *Eur. J. Pharmacol.* 888, 173459. doi:10.1016/j.ejphar.2020.173459

Zhu, Y. G., Feng, X. M., Abbott, J., Fung, X. H., Hao, Q., Monsel, A., et al. (2014). Human mesenchymal stem cell Microvesicles for treatment of *Escherichia coli* Endotoxicin-induced acute lung injury in mice. *Stem Cells* 32 (1), 116–125. doi:10.1002/stem.1504

Zhu, Z. X., Huang, J. G., Li, X., Xing, J., Chen, Q., Liu, R. L., et al. (2020). Gut microbiota regulate tumor metastasis via circRNA/miRNA networks. *Gut Microbes* 16, 1788891. doi:10.1080/194409976.2020.1788891